Indiana life science players have adapted to pandemic, panelists say
FREE NEWSLETTERS
April 16, 2021
Unlike other sectors of the economy that have been battered by the pandemic, including restaurants, travel and hospitality, life science organizations seem to have largely weathered the lockdown, with some even raising records funds, taking on huge expansions, hiring new employees and reporting higher productivity.
That was consensus of a group of speakers Friday morning at the IBJ Life Sciences Power Panel, representing large corporations, research institutions and startups.
Companies have learned to operate in remote settings, through video conferences, email and other technologies.
“It’s a virtual world,” said Jeff Simmons, president and CEO of Elanco Animal Health, a Greenfield-based maker of animal vaccines and feeds for livestock and pets. “We feel we’re at least 25% more productive. So the tragedy would be coming out of COVID and not keeping a lot of the silve
Virtual panel of startup, commercialization experts to explore tech transfer in Indiana
Startup leaders from Purdue University and across the state of Indiana will provide insights into technology transfer during The Frameworx Tech Transfer in Indiana virtual panel event. (Purdue University image)
WEST LAFAYETTE, Ind. – Startup leaders from Purdue University and across the state of Indiana will provide insights into technology transfer during a virtual panel event Feb. 18.
The Frameworx Tech Transfer in Indiana panel also will feature startups from Indiana University and the University of Notre Dame. BioCrossroads, which released a report on tech transfer in Indiana, is hosting the event.
Boomerang Ventures to Open in 16 Tech Innovation District insideindianabusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insideindianabusiness.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Decio Eizirik, MD, PhD, Scientific Director of the Indiana Biosciences Research Institute Diabetes Center. view more
Credit: Indiana Biosciences Research Institute
Indianapolis, Ind. - A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center s Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for autoimmune diseases requires studying together the immune system AND target tissues. This study, Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis and rheumatoid arthritis, is featured in the Jan. 6, 2021, edition of
Science Advances. We must move away from the present immune-centric-only view of autoimmune diseases, explains Eizirik. Indeed, trying to understand these diseases focusing on the immune system only, and forgetting the target tissues, may be similar to attempting to fly a plane with only one wing.